TerrAscend (TSNDF) Income from Non-Controlling Interests (2021 - 2026)
TerrAscend's (TSNDF) quarterly Income from Non-Controlling Interests came in at $1.1 million in Q1 2026, down 18.89% year-on-year from $1.3 million in Q1 2025, and down 5.04% on a QoQ basis from $1.1 million in Q4 2025.
TerrAscend (TSNDF) Income from Non-Controlling Interests (2021 - 2026) Analysis & Trends
TerrAscend (TSNDF) has 6 years of Income from Non-Controlling Interests data on file, last reported at $1.1 million in Q1 2026.
- On a quarterly basis, Income from Non-Controlling Interests fell 18.89% year-over-year to $1.1 million in Q1 2026; TTM through Mar 2026 was $4.7 million, a 30.17% decrease from a year earlier, with the FY2025 full-year figure at $4.9 million, down 35.24% from the prior year.
- Income from Non-Controlling Interests for Q1 2026 stood at $1.1 million, down from $1.1 million in the prior quarter.
- Over the last five years, Income from Non-Controlling Interests for TSNDF reached as high as $2.3 million in Q4 2023 and fell as low as $351000.0 in Q1 2022.
- Historically, Income from Non-Controlling Interests has averaged $1.6 million across 5 years, with a median of $1.7 million in 2024.
- Across the five-year window, Income from Non-Controlling Interests soared 522.79% in 2023 and plunged 40.93% in 2025, its largest moves.
- Year by year, Income from Non-Controlling Interests stood at $1.0 million in 2022, then jumped by 124.66% to $2.3 million in 2023, then retreated by 27.42% to $1.7 million in 2024, then slumped by 34.05% to $1.1 million in 2025, then fell by 5.04% to $1.1 million in 2026.
- Per Business Quant data, the three most recent Income from Non-Controlling Interests figures were $1.1 million in Q1 2026, $1.1 million in Q4 2025, and $1.2 million in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Inc. Minority (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 89.42 Bn | 87.55 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 35.91 Bn | 32.16 Bn | 1.97 Bn | - |
| 3 | Zoetis | 32.72 Bn | 30.78 Bn | 1.62 Bn | - |
| 4 | Takeda Pharmaceutical | 27.65 Bn | 23.59 Bn | 4.39 Bn | 395,346.10 |
| 5 | United Therapeutics | 23.11 Bn | 20.96 Bn | 648.10 Mn | - |
| 6 | RedHill Biopharma | 21.80 Bn | 21.80 Bn | - | - |
| 7 | Viatris | 20.30 Bn | 18.50 Bn | 1.16 Bn | - |
| 8 | Neurocrine Biosciences | 17.88 Bn | 16.56 Bn | 800.70 Mn | -12.70 Mn |
| 9 | Elanco Animal Health | 12.65 Bn | 12.22 Bn | 785.00 Mn | - |
| 10 | TerrAscend | 161.95 Mn | 161.48 Mn | 34.60 Mn | 1.06 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 1.06 Mn |
| Dec 31, 2025 | 1.11 Mn |
| Sep 30, 2025 | 1.21 Mn |
| Jun 30, 2025 | 1.28 Mn |
| Mar 31, 2025 | 1.30 Mn |
| Dec 31, 2024 | 1.69 Mn |
| Sep 30, 2024 | 1.73 Mn |
| Jun 30, 2024 | 1.94 Mn |
| Mar 31, 2024 | 2.20 Mn |
| Dec 31, 2023 | 2.32 Mn |
| Sep 30, 2023 | 2.16 Mn |
| Jun 30, 2023 | 2.14 Mn |
| Mar 31, 2023 | 2.19 Mn |
| Dec 31, 2022 | 1.03 Mn |
| Sep 30, 2022 | 2.23 Mn |
| Jun 30, 2022 | 945,000.00 |
| Mar 31, 2022 | 351,000.00 |
| Dec 31, 2021 | 556,000.00 |
| Sep 30, 2021 | 1.41 Mn |
| Jun 30, 2021 | 998,000.00 |